Cargando…

Assessment of Growth Reduction of Five Clinical Pathogens by Injectable S53P4 Bioactive Glass Material Formulations

The one-stage treatment of chronic osteomyelitis with S53P4 bioactive glass (BAG) granules has shown excellent results. However, these granules possess suboptimal handling properties. Therefore, new injectable S53P4 putty materials have been developed by the incorporation of a synthetic binder to co...

Descripción completa

Detalles Bibliográficos
Autores principales: Thijssen, Eline G. J., van Gestel, Nicole A. P., Bevers, Raymond, Hofmann, Sandra, Geurts, Jan, van Loo, Inge H. M., Arts, J. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333246/
https://www.ncbi.nlm.nih.gov/pubmed/32676498
http://dx.doi.org/10.3389/fbioe.2020.00634
_version_ 1783553710442414080
author Thijssen, Eline G. J.
van Gestel, Nicole A. P.
Bevers, Raymond
Hofmann, Sandra
Geurts, Jan
van Loo, Inge H. M.
Arts, J. J.
author_facet Thijssen, Eline G. J.
van Gestel, Nicole A. P.
Bevers, Raymond
Hofmann, Sandra
Geurts, Jan
van Loo, Inge H. M.
Arts, J. J.
author_sort Thijssen, Eline G. J.
collection PubMed
description The one-stage treatment of chronic osteomyelitis with S53P4 bioactive glass (BAG) granules has shown excellent results. However, these granules possess suboptimal handling properties. Therefore, new injectable S53P4 putty materials have been developed by the incorporation of a synthetic binder to contain glass granules. The goal of the current study was to assess their potential to eradicate five clinically relevant pathogens: methicillin sensitive Staphylococcus aureus (MSSA), methicillin resistant Staphylococcus aureus (MRSA), Enterococcus coli (E. coli), Enterococcus faecalis (E. faecalis), and Pseudomonas aeruginosa (P. aeruginosa). As a control, S53P4 granules (500–800 μm) and S66 glass (< 45 μm) were used. To evaluate the antimicrobial properties, the materials were cultured with the pathogens in a Müller-Hinton II broth for a week with daily colony forming unit (CFU) counting. One of the tested putty formulations was observed to reduce the number of CFU/mL compared to a negative control (no material, only pathogen in broth) for E. coli, E. faecalis and P. aeruginosa. However, none of the tested putty formulations was able to completely eradicate the pathogens in the broths, which would be needed for safe infection treatment. The results obtained for the control materials were unexpected. S66 glass showed full eradication of P. aeruginosa and reduced the number of CFUs of other pathogens, while the S53P4 granules did not show eradication. The observations on the loose S53P4 granules in this study contradict available literature, which needs further investigation. The results obtained in this study also stretch the importance for a better understanding of the underlying antimicrobial mechanism of S53P4 BAG and how this is related to the dosage. In addition, it should be elucidated how these antimicrobial properties are affected by changes in the material formulation, for example by addition of binders to improve the handling properties or by changing the surface area.
format Online
Article
Text
id pubmed-7333246
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73332462020-07-15 Assessment of Growth Reduction of Five Clinical Pathogens by Injectable S53P4 Bioactive Glass Material Formulations Thijssen, Eline G. J. van Gestel, Nicole A. P. Bevers, Raymond Hofmann, Sandra Geurts, Jan van Loo, Inge H. M. Arts, J. J. Front Bioeng Biotechnol Bioengineering and Biotechnology The one-stage treatment of chronic osteomyelitis with S53P4 bioactive glass (BAG) granules has shown excellent results. However, these granules possess suboptimal handling properties. Therefore, new injectable S53P4 putty materials have been developed by the incorporation of a synthetic binder to contain glass granules. The goal of the current study was to assess their potential to eradicate five clinically relevant pathogens: methicillin sensitive Staphylococcus aureus (MSSA), methicillin resistant Staphylococcus aureus (MRSA), Enterococcus coli (E. coli), Enterococcus faecalis (E. faecalis), and Pseudomonas aeruginosa (P. aeruginosa). As a control, S53P4 granules (500–800 μm) and S66 glass (< 45 μm) were used. To evaluate the antimicrobial properties, the materials were cultured with the pathogens in a Müller-Hinton II broth for a week with daily colony forming unit (CFU) counting. One of the tested putty formulations was observed to reduce the number of CFU/mL compared to a negative control (no material, only pathogen in broth) for E. coli, E. faecalis and P. aeruginosa. However, none of the tested putty formulations was able to completely eradicate the pathogens in the broths, which would be needed for safe infection treatment. The results obtained for the control materials were unexpected. S66 glass showed full eradication of P. aeruginosa and reduced the number of CFUs of other pathogens, while the S53P4 granules did not show eradication. The observations on the loose S53P4 granules in this study contradict available literature, which needs further investigation. The results obtained in this study also stretch the importance for a better understanding of the underlying antimicrobial mechanism of S53P4 BAG and how this is related to the dosage. In addition, it should be elucidated how these antimicrobial properties are affected by changes in the material formulation, for example by addition of binders to improve the handling properties or by changing the surface area. Frontiers Media S.A. 2020-06-26 /pmc/articles/PMC7333246/ /pubmed/32676498 http://dx.doi.org/10.3389/fbioe.2020.00634 Text en Copyright © 2020 Thijssen, van Gestel, Bevers, Hofmann, Geurts, van Loo and Arts. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Thijssen, Eline G. J.
van Gestel, Nicole A. P.
Bevers, Raymond
Hofmann, Sandra
Geurts, Jan
van Loo, Inge H. M.
Arts, J. J.
Assessment of Growth Reduction of Five Clinical Pathogens by Injectable S53P4 Bioactive Glass Material Formulations
title Assessment of Growth Reduction of Five Clinical Pathogens by Injectable S53P4 Bioactive Glass Material Formulations
title_full Assessment of Growth Reduction of Five Clinical Pathogens by Injectable S53P4 Bioactive Glass Material Formulations
title_fullStr Assessment of Growth Reduction of Five Clinical Pathogens by Injectable S53P4 Bioactive Glass Material Formulations
title_full_unstemmed Assessment of Growth Reduction of Five Clinical Pathogens by Injectable S53P4 Bioactive Glass Material Formulations
title_short Assessment of Growth Reduction of Five Clinical Pathogens by Injectable S53P4 Bioactive Glass Material Formulations
title_sort assessment of growth reduction of five clinical pathogens by injectable s53p4 bioactive glass material formulations
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333246/
https://www.ncbi.nlm.nih.gov/pubmed/32676498
http://dx.doi.org/10.3389/fbioe.2020.00634
work_keys_str_mv AT thijssenelinegj assessmentofgrowthreductionoffiveclinicalpathogensbyinjectables53p4bioactiveglassmaterialformulations
AT vangestelnicoleap assessmentofgrowthreductionoffiveclinicalpathogensbyinjectables53p4bioactiveglassmaterialformulations
AT beversraymond assessmentofgrowthreductionoffiveclinicalpathogensbyinjectables53p4bioactiveglassmaterialformulations
AT hofmannsandra assessmentofgrowthreductionoffiveclinicalpathogensbyinjectables53p4bioactiveglassmaterialformulations
AT geurtsjan assessmentofgrowthreductionoffiveclinicalpathogensbyinjectables53p4bioactiveglassmaterialformulations
AT vanlooingehm assessmentofgrowthreductionoffiveclinicalpathogensbyinjectables53p4bioactiveglassmaterialformulations
AT artsjj assessmentofgrowthreductionoffiveclinicalpathogensbyinjectables53p4bioactiveglassmaterialformulations